Uveitis Clinical Trial
Official title:
A Clinical Trial of Oral Acyclovir in Viral Uveitis
NCT number | NCT03389191 |
Other study ID # | 2017KY-07 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2017 |
Est. completion date | December 2021 |
Verified date | April 2021 |
Source | Tianjin Medical University |
Contact | Xiaomin Zhang, M.D. |
Phone | +86-13920023990 |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project is designed to test the hypothesis that acyclovir is clinically useful for patients with refractory viral uveitis.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2021 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age between 18 and above. - Chronic, vision threatening viral uveitis. - Patients can't tolerate hormone therapy bacause of drug side effects. - Consent to undergo anterior chamber tap and give aqueous for the study. - Able to undergo relevant tests. - Able to come for subsequent follow-up visits. - Ability to provide informed consent. Exclusion Criteria: - Patients who are allergic to ayclovir. - Immunocompromised patients - Positive for HIV, Hep B and Hep C - Not keen on participating in the study - Patients who are incapable, either by law or mental state, of giving consents in their own right. - Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol. - Patients who are pregnant or breastfeeding. - Any other specified reason as determined by the clinical investigator. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University Eye Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Xiaomin Zhang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean and median change in best corrected visual acuity in logMAR | Mean and median change in best corrected visual acuity in logMAR | 12 weeks | |
Secondary | Number of participants who experience a recurrence | Number of participants who experience a recurrence | 12 weeks | |
Secondary | Length of time to quiescence | Length of time to quiescence | 12 weeks | |
Secondary | Ability to taper concomitant immunosuppressive medications | Ability to taper concomitant immunosuppressive medications | 12 weeks | |
Secondary | Number and severity of systemic and ocular toxicities and adverse events | Number and severity of systemic and ocular toxicities and adverse events | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Withdrawn |
NCT01280669 -
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
|
Phase 2 | |
Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|